I am in the last stages of a first article draft on how UK-US pharma house Burroughs Wellcome (BW) priced the first successful treatment...

As of end of January 2021, concerns in Japan grow over domestic production of vaccines, as Chief Cabinet Secretary Kato Katsunobu has...

WHO has developed an R&D Blueprint Team to globally coordinate candidate vaccines. The agency calls vaccine efforts ‘unprecedented’,...

A happy new year to all of you! I hope you all made some exciting and rejuvenating resolutions for 2021 J The COVID-19 pandemic story...

I have been quite busy with book writing, but here are a few updates, starting with Japan’s public health measures after lifting the...

As we get into late May and various countries are considering lifting lockdown, I’d like to post this weekend a brief overview of three...

It was announced on 13 May 2020 that Fujirebio had developed a testing kit that can measure seropositivity in 30 minutes and will be used...

Which comes first: developing accurate diagnostic testing or accurate measures of death rates? Severity of COVID-19 fatality rates has...

In addition to fast-tracking Remdesivir[1], other treatments and vaccines are being explored in Japan. Globally, on 8 May, Japan pledged...

In other news, Japan’s prolonged emergency state was recently announced to be reassessed on 14 May by an expert and the month will work...

A quick post to share an alternative view of nutrition, immune strength and metabolic syndrome in the COVID-19 response, since much of...

This is a brief update/summary post to follow up my first post on production capacity and Indian generics. Key to note is that...

Indian generics, hydroxychloroquine and production capacity in global emergency Indian generics are currently playing an important role...

As a contemporary historian of the global AIDS response, I am interested in how societies across the world respond to epidemics. The...